Lehmann, Anja http://orcid.org/0000-0001-7672-2374
Geburek, Ina
Hessel-Pras, Stefanie http://orcid.org/0000-0002-6153-0035
Enge, Anne-Margarethe
Mielke, Hans http://orcid.org/0000-0001-7127-8112
Müller-Graf, Christine http://orcid.org/0000-0002-0122-7528
Kloft, Charlotte
Hethey, Christoph http://orcid.org/0000-0003-2839-3902
Funding for this research was provided by:
Bundesinstitut für Risikobewertung (BfR)
Article History
Received: 13 December 2023
Accepted: 31 January 2024
First Online: 25 March 2024
Declarations
:
: Charlotte Kloft reports grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, Astra Zeneca, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk and Sanofi) for the PharMetrX PhD program and from the Innovative Medicines Initiative-Joint Undertaking (‘DDMoRe’). The other authors declare that they have no conflict of interest.